A peptide-based tolerizing vaccine expanded protective regulatory T cells and suppressed autoimmune arthritis in mice without broadly suppressing the immune system.
Dominant transferable toleranceRegulatory T cells generated by the peptide vaccine could be transferred to untreated mice and still suppressed arthritis — a key benchmark for true immune tolerance.
What the researchers found
Researchers developed a peptide-based tolerizing vaccine using a galactosylated collagen type II peptide bound to an MHC class II protein (Aq-galCOL2) that directly interacts with disease-driving T cells in autoimmune arthritis. The vaccine expanded a special population of VISTA-positive regulatory T cells that suppressed the autoimmune attack.
Critically, the therapeutic effect was dominant — meaning the protective regulatory T cells could be transferred to other mice and still suppress arthritis. The approach also proved tissue-specific, working across multiple arthritis models including antibody-induced arthritis. This represents a fundamentally different strategy from current arthritis treatments, which broadly suppress the immune system rather than targeting only the disease-causing cells.
Why it matters
Current treatments for rheumatoid arthritis — like methotrexate and biologics — suppress the entire immune system, increasing infection risk. A tolerizing vaccine that only targets the specific T cells driving joint destruction would leave the rest of the immune system intact. This 'antigen-specific' approach has been a holy grail of autoimmune research for decades, and this study demonstrates it's achievable in principle, with potential applicability beyond arthritis to other autoimmune diseases.
How the study worked
The researchers engineered an MHC class II protein loaded with a modified collagen peptide (galactosylated COL2) and administered it to mice with autoimmune arthritis models. They tracked the expansion of regulatory T cells, measured disease suppression, and performed adoptive transfer experiments — moving regulatory T cells from treated mice into untreated mice — to confirm the dominant, transferable nature of the immune tolerance. Multiple arthritis models were tested, including antibody-induced arthritis.
Who was studied
Mouse models of autoimmune arthritis (multiple models including collagen-induced and antibody-induced arthritis)
What this study cannot tell us
This is entirely a mouse study — the MHC proteins used are specific to mice (Aq), and human translation would require matching human HLA molecules. The complexity of manufacturing MHC-peptide complexes for diverse human HLA types could be a significant barrier to clinical development. Long-term durability of the tolerogenic effect and safety in humans remain unknown.
How to read the evidence
This is a preclinical study in mouse models, published in the high-impact journal PNAS. While the results are compelling, no human data exists, keeping the evidence at the preliminary stage.
When this study was published
Published in 2023 in PNAS. This represents recent, active research in peptide-based immune tolerance — a rapidly evolving field.
The bigger picture
Antigen-specific tolerance has been called the holy grail of autoimmune therapy because it would treat the root cause — misguided immune targeting — without the infection risks of broad immunosuppression. While peptide-based tolerance approaches have been explored before, achieving dominant, transferable suppression (where the protective effect persists and spreads) has been elusive. This study marks meaningful progress toward that goal, with implications far beyond arthritis if the approach can be adapted to other autoimmune antigens.
Questions still open
- Can this approach be translated to human HLA molecules, which are far more diverse than mouse MHC?
- How long does the tolerogenic effect last, and would booster doses be needed?
- Could this same strategy be adapted for other autoimmune diseases like type 1 diabetes or multiple sclerosis?
Common questions
How is a tolerizing vaccine different from a regular vaccine?
Why can't current arthritis drugs do what this vaccine does?
Read the original research
Therapy targeting antigen-specific T cells by a peptide-based tolerizing vaccine against autoimmune arthritis.
Proceedings of the National Academy of Sciences of the United States of America, 120(25), e2218668120
Citation
Urbonaviciute, Vilma; Romero-Castillo, Laura; Xu, Bingze; Luo, Huqiao; Schneider, Nadine; Weisse, Sylvia; Do, Nhu-Nguyen; Oliveira-Coelho, Ana; Fernandez Lahore, Gonzalo; Li, Taotao; Sabatier, Pierre; Beusch, Christian M; Viljanen, Johan; Zubarev, Roman A; Kihlberg, Jan; Bäcklund, Johan; Burkhardt, Harald; Holmdahl, Rikard. (2023). Therapy targeting antigen-specific T cells by a peptide-based tolerizing vaccine against autoimmune arthritis.. Proceedings of the National Academy of Sciences of the United States of America, 120(25), e2218668120. https://doi.org/10.1073/pnas.2218668120